These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18210097)

  • 1. Predictors of orphan drug approval in the European Union.
    Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
    Eur J Clin Pharmacol; 2008 May; 64(5):545-52. PubMed ID: 18210097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
    Harada K; Toriyabe K; Ono S
    J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
    Brabers AE; Moors EH; van Weely S; de Vrueh RL
    Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
    Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
    BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
    Joppi R; Bertele' V; Garattini S
    Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies.
    Roberts SW; Elvang TLB; Syed L; Samuelsen MB; Arp-Hansen EL; Nielsen HK; Lund IK; Dünweber DL; Listov-Saabye N; Bjørn-Larsen D; Hjelmsmark A; Mikkelsen TA
    Ther Innov Regul Sci; 2023 Mar; 57(2):386-395. PubMed ID: 36401076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European regulation on orphan medicinal products: 10 years of experience and future perspectives.
    ; Westermark K; Holm BB; Söderholm M; Llinares-Garcia J; Rivière F; Aarum S; Butlen-Ducuing F; Tsigkos S; Wilk-Kachlicka A; N'Diamoi C; Borvendég J; Lyons D; Sepodes B; Bloechl-Daum B; Lhoir A; Todorova M; Kkolos I; Kubáčková K; Bosch-Traberg H; Tillmann V; Saano V; Héron E; Elbers R; Siouti M; Eggenhofer J; Salmon P; Clementi M; Krieviņš D; Matulevičiene A; Metz H; Vincenti AC; Voordouw A; Dembowska-Bagińska B; Nunes AC; Saleh FM; Foltánová T; Možina M; Torrent i Farnell J; Beerman B; Mariz S; Evers MP; Greene L; Thorsteinsson S; Gramstad L; Mavris M; Bignami F; Lorence A; Belorgey C
    Nat Rev Drug Discov; 2011 May; 10(5):341-9. PubMed ID: 21532564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Removal of the EMA orphan designation upon request of the sponsor: cui prodest?
    Montanaro N; Bonaldo G; Motola D
    Eur J Clin Pharmacol; 2021 Jul; 77(7):1057-1063. PubMed ID: 33501508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
    Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
    Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 18. No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study.
    Stolk P; Heemstra HE; Leufkens HG; Bloechl-Daum B; Heerdink ER
    Orphanet J Rare Dis; 2009 Dec; 4():27. PubMed ID: 20003427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.